» Articles » PMID: 16434648

Disability Progression in Multiple Sclerosis is Slower Than Previously Reported

Overview
Journal Neurology
Specialty Neurology
Date 2006 Jan 26
PMID 16434648
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate disease progression and risk factors in a large geographically based population with multiple sclerosis (MS), using two different inception points--clinical onset and date of birth.

Methods: The authors reviewed a database of subjects with definite MS and symptom onset prior to July 1988. The main outcome was sustained progression to Expanded Disability Status Scale (EDSS) 6 (requires a cane), using the date of birth and date of MS onset as inception points in separate analyses. Risk factors examined were sex, relapsing vs primary progressive course, onset age, and onset symptoms.

Results: The study included 2,837 patients, followed prospectively for 22,723 patient years. The median time to EDSS 6 was 27.9 years, 15 years after onset; only 21% reached EDSS 6, and by age 50, 28% required a cane. Men progressed 38% more quickly than women from onset (p < 0.0005), yet both required canes at similar ages: 58.8 years for men and 60.1 for women (p = 0.082). A younger onset age predicted a slower progression, but those older at onset were consistently older when reaching EDSS 6. A primary progressive course predicted a more rapid progression from both onset (p < 0.0005) and birth (hazard ratio = 2.7 [95% CI: 2.2 to 3.3]). No onset symptom consistently predicted progression.

Conclusion: Disability progression in multiple sclerosis (MS) accrued more slowly than found in earlier longitudinal studies. The authors also challenged two fundamental concepts in MS, demonstrating that neither male sex nor older onset age was associated with worse disease outcome.

Citing Articles

Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis.

Rad L, Hughes K, Wheeler S, Decker J, Orbach S, Galvan A Proc Natl Acad Sci U S A. 2025; 122(7):e2409852122.

PMID: 39937858 PMC: 11848328. DOI: 10.1073/pnas.2409852122.


Demographic and Clinical Predictors of Disease Severity in Patients With Multiple Sclerosis: A Retrospective Cross-Sectional Analysis.

Almuklass A, Gosty G, Alotaibi E, Alharbi B, AlShayea R, Aba Alkhail A Cureus. 2023; 15(10):e46873.

PMID: 37954739 PMC: 10638286. DOI: 10.7759/cureus.46873.


Physical Activity Together for Multiple Sclerosis (PAT-MS): A randomized controlled feasibility trial of a dyadic behaviour change intervention.

Fakolade A, Awadia Z, Cardwell K, McKenna O, Venasse M, Hume T Contemp Clin Trials Commun. 2023; 36:101222.

PMID: 37928934 PMC: 10622616. DOI: 10.1016/j.conctc.2023.101222.


Potential biological contributers to the sex difference in multiple sclerosis progression.

Alvarez-Sanchez N, Dunn S Front Immunol. 2023; 14:1175874.

PMID: 37122747 PMC: 10140530. DOI: 10.3389/fimmu.2023.1175874.


Factors associated with time to disability progression in patients with multiple sclerosis.

Arteaga-Noriega A, Castro-Alvarez J, Benjumea-Bedoya D, Gutierrez-Vargas J, Segura-Cardona A, Gonzalez-Gomez D Rev Peru Med Exp Salud Publica. 2023; 39(4):442-449.

PMID: 36888806 PMC: 11397597. DOI: 10.17843/rpmesp.2022.394.11433.